William Blair & Company
AVXL icon

William Blair & Company’s Anavex Life Sciences AVXL Stock Holding History

William Blair & Company’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,200
Closed -$62.1K – 1826
2024
Q1 		$62.1K Hold
12,200
– – ﹤0.01% 1576
2023
Q4 		$114K Hold
12,200
– – ﹤0.01% 1488
2023
Q3 		$79.9K Buy
+12,200
New +$97.1K ﹤0.01% 1532

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

William Blair & Company's AVXL Position: Q2 2024 in Review

William Blair & Company sold out of Anavex Life Sciences (AVXL) in Q2 2024, closing a stake of 12,200 shares — an estimated $62.1K sold.

William Blair & Company first reported a position in AVXL in Q3 2023 and held it in 3 quarters. The position peaked at $114K in Q4 2023. 141 funds tracked by Wall St. Rank hold AVXL as of Q2 2024.

  • William Blair & Company reported no remaining Anavex Life Sciences position as of Q2 2024 after selling out during the quarter.
  • William Blair & Company sold 12,200 Anavex Life Sciences shares in Q2 2024, an estimated $62.1K.
  • William Blair & Company first reported a position in Anavex Life Sciences in Q3 2023 and held it in 3 quarters.
  • William Blair & Company's Anavex Life Sciences position peaked at $114K in Q4 2023.
  • 141 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2024.

Based on William Blair & Company's 13F filing for Q2 2024, filed 12 Aug 2024.